Target 2035 – update on the quest for a probe for every protein
Susanne Müller(Goethe University Frankfurt), Matthieu Schapira(University of Toronto), Ian Collins(Institute of Cancer Research), Adrian J. Carter(Boehringer Ingelheim (Germany)), Bissan Al‐Lazikani(Institute of Cancer Research), Brian D. Marsden(Centre for Human Genetics), Stefan Knapp(Goethe University Frankfurt), A.M. Edwards(University of Toronto), Evert Homan(Goethe University Frankfurt), Maxwell R. Morgan(University of Toronto), Jan Dreher(Bayer (Germany)), Shaunna Beedie(University of Oxford), Matthew D. Hall(National Institutes of Health), David A. Brown(Galveston College), S. Lindemann(Merck KGaA, Darmstadt (Germany)), Natarajan Kannan(University of Georgia), Stephen V. Frye(University of North Carolina at Chapel Hill), Ursula Egner(Nuvisan (Germany)), Alessio Ciulli(University of Dundee), Andrew R. Leach(LifeArc), Kristina Edfeldt(Karolinska University Hospital), Jonathan B. Baell(Nanjing Tech University), Dafydd R. Owen(Pfizer (United States)), James R. Kiefer(Goethe University Frankfurt), G.A. Bezerra(University of Oxford), Stephen Hitchcock(Takeda (United States)), Hisanori Matsui(Takeda (Japan)), Albert A. Antolín(Institute of Cancer Research), Jordan L. Meier(National Institutes of Health), Maurice Michel(Goethe University Frankfurt), Stephen M. Fuchs(University of North Carolina at Chapel Hill), A. Chaikuad(Goethe University Frankfurt), Paul E. Brennan(Discovery Centre), Alex N. Bullock(Discovery Centre), David H. Drewry(University of North Carolina at Chapel Hill), Daniel Merk(Goethe University Frankfurt), Hartmut Beck(Bayer (Germany)), Stefan Kubicek(Austrian Academy of Sciences), Mathilde Chaineau(Montreal Neurological Institute and Hospital), Peter J. Brown(University of Toronto), Benjamin Perry(Drugs for Neglected Diseases Initiative), Kumar Singh Saikatendu(Takeda (United States)), Milka Kostić, Suzanne Ackloo, Alexander Hillisch(UCB Pharma (Germany)), Ulrich A. K. Betz(Bayer (Germany)), Anke Mueller‐Fahrnow(Bayer (Germany)), Ingo V. Hartung(Merck KGaA, Darmstadt (Germany)), Saul H. Rosenberg(Abbott Fund), Arij Al Chawaf(University of Toronto)
Cited by 83
Related Papers
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
|Journal of Molecular Biology|1997|6.7k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ChEMBL: towards direct deposition of bioassay data
|Nucleic Acids Research|2018|2.5k
The ChEMBL database in 2017
|Nucleic Acids Research|2016|2.4k